The National Institutes of Health funded a trial recruited by 25,871 healthy men and women in America aged 50 and over, including 5,106 African Americans. Study participants were divided into four groups and were randomly assigned to take supplements or placebo and were followed by 5.3 years on average.
One group took 2,000 IU (international units) of vitamin D3 and 1 grams of omega-3 per day. The other group received vitamin D and a fake pill instead of omega-3. The third group received omega-3 and vitamin D placebo. And the last group received two placebo.
Pharmavite LLC Northridge, California, donated vitamin D agents and appropriate placebo, and Pronova BioPharma from Norway and BASF donated Omacor, a fish oil sold under the Lovaza brand in the United States.
The results, published in The New England Journal of Medicine, were presented at a conference of the American Heart Association in Chicago on Saturday.
In many ways, the results are not surprising. The public has been frozen by constant breaks of information about the health benefits of vitamin D in recent years, as studies have linked low levels of vitamins with conditions that are different, such as diabetes, high blood pressure, cancer, heart disease, and depression. Many doctors in primary care now routinely test the level of vitamin D patients and declare them deficient, and sales have jumped over the last few years.
However, all the time critics have questioned whether vitamin D is only a mark of overall health and whether the deficit threshold is set too high. Tzv. Vitamin sun is synthesized in the body when the skin is exposed to sunlight and is exhausted by smoking, obesity, poor nutrition and other factors. Certain foods, such as fatty fish, eggs and fortified milk, also contain vitamin D.
The Institute of Medicine in 2011 concluded that most Americans get enough vitamin D and that the disadvantages are exaggerated. The group also noted that reports of potential benefits with higher blood levels were inconsistent.